Table A1.
Best Response According to Histology
| Histology | No. of Patients | CR | PR | SD | PD | NE | ORR (%) |
|
|---|---|---|---|---|---|---|---|---|
| ITT (N = 56) | Evaluable (n = 50) | |||||||
| CLL/SLL | 16 | 2 | 9 | 3* | 2 | 69 | 79 | |
| MCL | 9 | 3 | 4 | 1 | 1 | 78 | 78 | |
| WM | 4 | 3 | 1 | 75 | 75 | |||
| FL | 16 | 3 | 3 | 4 | 3 | 3 | 38 | 46 |
| MZL/MALT | 4 | 1 | 1 | 1 | 1 | 25 | 33 | |
| DLBCL | 7 | 2 | 1 | 4 | 29 | 29 | ||
| Total | 56 | 8 | 22 | 11 | 9 | 6 | 54 | 60 |
Abbreviations: CLL, chronic lymphocytic leukemia; CR, complete response; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; ITT, intent to treat; MCL, mantle-cell lymphoma; MZL/MALT, marginal zone/mucosal-associated lymphoid tissue lymphoma; NE, not evaluable; ORR, overall response rate; PD, disease progression; PR, partial response; SD, stable disease; SLL, small lymphocytic lymphoma; WM, Waldenström macroglobulinemia.
*
One patient with CLL had nodal response with lymphocytosis.